Our story started when Nuclear Power Institute of China started research of isotopes In the 1970s. After the successful transition in the early 2000s, Chengdu Gaotong Isotope maintained our leading role in the industry as a member of CIRC.
Obtained GMP recertification for radiopharmaceutical production facilities.
Built the Instant-Labeled Drug Center together with HTA. Co. Ltd.
China Isotope & Radiation Corporation was established as CNNC’s nuclear technology application platform . It has since become the biggest shareholder of Chengdu Gaotong Isotope.
Obtained certificate of approval for the quality, environment, and occupational health and safety management system
Strontium [Sr-89] Chloride Injection was listed as an important provincial project of Sichuan by the authority.
Obtained regulatory approval for Strontium Chloride [Sr-89] injection and 3 types of B(U) containers from China Food and Drug Administration and China Nuclear Safety Administration.
New production facility of Sodium Iodine [I-131] Oral Solution was set up
Obtained GMP certificate for radiopharmaceutical production facilities.
Chengdu Gaotong Isotope Co., Ltd. (CNNC) was established.
Low-activity sealed radioactive source production facility was set up.
Developed dry distillation process to produce I-131; Production facility of the said process was set up.
The radiopharmaceutical production facilities were set up by NPIC. The first commercial gel-type Tc-99m generator production facility in the world was built and became an IAEA demonstration project.
The first sealed radioactive source production facility with the capability of one million curies of Co-60 was set up in China.
NPIC began R&D of sealed radioactive sources.
NPIC began R&D of radiopharmaceuticals.